Table 1 Patient, Tumour and Treatment Characteristics
|  | Subgroup | Number (n = 32) (%) |
|---|---|---|
Age at Diagnosis | < 40 yrs | 17 |
> 40 yrs | 15 | |
Median | 38 yrs | |
Number of Craniotomy prior to RT | 1 | 23 (72%) |
2 | 4 (12%) | |
3 or more | 5 (16%) | |
Timing of RT | At initial diagnosis | 15 (47%) |
1st relapse | 12 (38%) | |
2nd relapse | 2 (6%) | |
Later | 3 (9%) | |
Pathology WHO 2016 | AOD | 12 (37%) |
| Â | AAmut | 20 (63%) |
Ki67% (preIMRT Surgery) Ki67% (prior Surgery) | Median (n = 22) | 10.0% (q1–3: 5.0–16.2) |
|  | Median (n = 10) | 5.0% (q1–3: 2.5–6.5) |
ATRX | Retained | 16 (50%) |
Lost | 8 (25%) | |
Unknown | 8 (25%) | |
Pre-Treatment Gad enhancement | Nil | 27 (84%) |
|  | < 10 mm | 4 (12%) |
|  | > 10 mm / diffuse | 1 (3%) |
Pre IMRT ECOGÂ performance status | 0 | 13 (41%) |
| Â | 1 | 17 (53%) |
| Â | 2 | 1 (3%) |
3 | 1 (3%) | |
IMRT Technique | Integrated Boost | 27 (84%) |
Single | 5 (16%) | |
Temozolomide | Nil | 7 (22%) |
Pre- and post-RT | 2 (6%) | |
Adjuvant post-RT | 23 (72%) |